Ieq Capital LLC Acquires New Position in Replimune Group, Inc. $REPL

Key Points

• Ieq Capital acquired 81,982 Replimune shares worth approximately $908,000 in the second quarter, while institutional investors collectively own 92.53% of the company.
• Replimune’s stock opened at $15.60, near its 12-month high of $16.15, despite the company reporting a quarterly EPS loss of $0.72 that missed estimates by $0.03.
• Analyst sentiment has improved, with several firms upgrading the stock; Replimune currently has a “Moderate Buy” consensus rating and an average price target of $12.00.

Ieq Capital LLC acquired a new position in shares of Replimune Group, Inc. (NASDAQ:REPL - Free Report) during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 81,982 shares of the company's stock, valued at approximately $908,000. Ieq Capital LLC owned 0.10% of Replimune Group as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Replimune Group by 17.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 44,352 shares of the company's stock valued at $435,000 after acquiring an additional 6,653 shares during the period. Millennium Management LLC raised its position in shares of Replimune Group by 2.8% during the 1st quarter. Millennium Management LLC now owns 1,223,236 shares of the company's stock worth $11,927,000 after purchasing an additional 33,574 shares during the period. Goldman Sachs Group Inc. lifted its holdings in shares of Replimune Group by 20.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 690,167 shares of the company's stock worth $6,729,000 after purchasing an additional 119,145 shares during the last quarter. Rhumbline Advisers lifted its holdings in shares of Replimune Group by 6.9% in the 2nd quarter. Rhumbline Advisers now owns 102,005 shares of the company's stock worth $948,000 after purchasing an additional 6,616 shares during the last quarter. Finally, Sei Investments Co. boosted its position in Replimune Group by 149.5% during the 2nd quarter. Sei Investments Co. now owns 30,478 shares of the company's stock valued at $283,000 after purchasing an additional 18,263 shares during the period. Institutional investors own 92.53% of the company's stock.

Insiders Place Their Bets

In other Replimune Group news, CFO Emily Luisa Hill sold 9,256 shares of the firm's stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $14.28, for a total transaction of $132,175.68. Following the transaction, the chief financial officer owned 215,852 shares of the company's stock, valued at approximately $3,082,366.56. This trade represents a 4.11% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Konstantinos Xynos sold 11,447 shares of the business's stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $12.97, for a total transaction of $148,467.59. Following the sale, the insider owned 224,215 shares in the company, valued at $2,908,068.55. This trade represents a 4.86% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders have sold 91,124 shares of company stock valued at $1,149,244. Corporate insiders own 5.40% of the company's stock.

Replimune Group Stock Down 1.8%

REPL opened at $15.60 on Friday. The stock's 50 day moving average price is $11.73 and its 200 day moving average price is $8.29. The company has a debt-to-equity ratio of 1.00, a current ratio of 5.23 and a quick ratio of 5.23. The stock has a market cap of $1.46 billion, a P/E ratio of -4.95 and a beta of 0.88. Replimune Group, Inc. has a 12 month low of $1.50 and a 12 month high of $16.15.

Replimune Group (NASDAQ:REPL - Get Free Report) last announced its quarterly earnings results on Friday, August 14th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.69) by ($0.03). As a group, research analysts predict that Replimune Group, Inc. will post -2.94 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the company. Wedbush upgraded Replimune Group from a "neutral" rating to an "outperform" rating and set a $12.00 price objective for the company in a research note on Friday, August 7th. Piper Sandler raised shares of Replimune Group from a "hold" rating to a "strong-buy" rating in a report on Friday, July 31st. Wolfe Research raised shares of Replimune Group to an "outperform" rating in a report on Tuesday, August 4th. Wall Street Zen raised shares of Replimune Group from a "strong sell" rating to a "sell" rating in a report on Saturday, May 23rd. Finally, BMO Capital Markets raised shares of Replimune Group from an "underperform" rating to an "outperform" rating and set a $16.00 price objective on the stock in a report on Tuesday, June 30th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $12.00.

Replimune Group Company Profile

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company's proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune's lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.

Want to see what other hedge funds are holding REPL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Replimune Group, Inc. (NASDAQ:REPL - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source